CL2015003413A1 - Stable formulation comprising iduronate-2-sulfatase protein and a polysorbate surfactant; container comprising said formulation; use of said formulation to treat hunters syndrome. - Google Patents

Stable formulation comprising iduronate-2-sulfatase protein and a polysorbate surfactant; container comprising said formulation; use of said formulation to treat hunters syndrome.

Info

Publication number
CL2015003413A1
CL2015003413A1 CL2015003413A CL2015003413A CL2015003413A1 CL 2015003413 A1 CL2015003413 A1 CL 2015003413A1 CL 2015003413 A CL2015003413 A CL 2015003413A CL 2015003413 A CL2015003413 A CL 2015003413A CL 2015003413 A1 CL2015003413 A1 CL 2015003413A1
Authority
CL
Chile
Prior art keywords
formulation
treat
iduronate
container
polysorbate surfactant
Prior art date
Application number
CL2015003413A
Other languages
Spanish (es)
Inventor
Gaozhong Zhu
Zahra Shahrokh
Jing Pan
Pericles Calias
Teresa Leah Wright
James Christian
Rick Fahrner
Kris Lowe
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of CL2015003413A1 publication Critical patent/CL2015003413A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULACIÓN ESTABLE PARA ADMINISTRACIÓN INTRATECAL QUE COMPRENDE LA PROTEÍNA IDURONATO-2-SULFATASA (I2S) Y POLISORBATO, LA CUAL ES ÚTIL PARA TRATAR SÍNDROME DE HUNTERS (DIVISIONAL DE SOL. N° 3657-12).STABLE FORMULATION FOR INTRATECAL ADMINISTRATION THAT INCLUDES PROTEIN IDURONATE-2-SULFATASE (I2S) AND POLYSORBATE, WHICH IS USEFUL TO TREAT HUNTERS SYNDROME (SOL DIVISION No. 3657-12).

CL2015003413A 2001-02-11 2015-11-20 Stable formulation comprising iduronate-2-sulfatase protein and a polysorbate surfactant; container comprising said formulation; use of said formulation to treat hunters syndrome. CL2015003413A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US44211501P 2001-02-11 2001-02-11
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
CL2015003413A1 true CL2015003413A1 (en) 2016-05-27

Family

ID=56081085

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015003221A CL2015003221A1 (en) 2001-02-11 2015-11-02 Stable pharmaceutical formulation for intrathecal administration comprising an arylsufatase (loop) protein, salt and a polysorbate surfactant and / or a buffering agent, and which may also contain a stabilizing agent; container comprising said formulation; use to treat metachromatic leukodystrophy (mld) disease
CL2015003413A CL2015003413A1 (en) 2001-02-11 2015-11-20 Stable formulation comprising iduronate-2-sulfatase protein and a polysorbate surfactant; container comprising said formulation; use of said formulation to treat hunters syndrome.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015003221A CL2015003221A1 (en) 2001-02-11 2015-11-02 Stable pharmaceutical formulation for intrathecal administration comprising an arylsufatase (loop) protein, salt and a polysorbate surfactant and / or a buffering agent, and which may also contain a stabilizing agent; container comprising said formulation; use to treat metachromatic leukodystrophy (mld) disease

Country Status (1)

Country Link
CL (2) CL2015003221A1 (en)

Also Published As

Publication number Publication date
CL2015003221A1 (en) 2016-05-06

Similar Documents

Publication Publication Date Title
EA200400730A1 (en) CONTROLLED DOSE INHALER
CO5660273A2 (en) PROTEIN AND HIGH CONCENTRATION ANTIBODY FORMULATIONS
CL2004000224A1 (en) STABLE PHARMACEUTICAL FORMULATION THAT INCLUDES AN IMMUNOGLOBULIN, A PHOSPHATE TAMPON, A POLYSORBATE AND SODIUM CHLORIDE, METHOD OF PREPARATION AND ITS USE.
AR029139A1 (en) STABILIZED INTERLEUQUINA 2
AR025925A1 (en) A COMPOSITION FOR A CHILD FORMULATION, A METHOD TO PRODUCE IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT OR A NUTRITIONAL PRODUCT DIRECTED TO MALNUTRITION.
ATE382057T1 (en) STABLE FORMULATION OF MODIFIED GLP-1
CY1108532T1 (en) UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
ECSP034895A (en) PHARMACEUTICAL COMPOSITIONS OF AMORFO DRUG ADSORBATES
RS49907B (en) Storable active substance concentrate with formoterol
NO995367L (en) Activated Vitamin D3 emulsion type solutions
CR7614A (en) INSULIN ACID PREPARATIONS WITH IMPROVED STABILITY
NO994409D0 (en) Stabilization of acid-sensitive benzimidazoles with amino acid / cyclodextrin combinations
CL2011001406A1 (en) "Stable liquid pharmaceutical formulation comprising an antibody to il-1beta (acz885), mannitol, histidine buffer and polysorbate 80, with a pH between 5.5-7.0".
NO20024221L (en) Mixtures containing alpha-2-adrenergic agonist components
HN2002000247A (en) SULFONAMIDE DERIVATIVES
DK1259226T3 (en) Anesthetic formulations
CY1107819T1 (en) PHARMACEUTICAL FORM OF OLANZAPIN
SE9800729D0 (en) New topical formulation I
ES2192070T3 (en) FORMULATION OF CONCENTRATION IN SUSPENSION WITH CONTENT IN PYRIMETHANIL.
PT1414467E (en) TOP TREATMENT OF MASTALGIA
BR0209155A (en) Pharmaceutical tablet having a high api content
CL2015003413A1 (en) Stable formulation comprising iduronate-2-sulfatase protein and a polysorbate surfactant; container comprising said formulation; use of said formulation to treat hunters syndrome.
IT1299264B1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF SKIN DISEASES ON AN INFLAMMATORY, IMMUNE OR PROLIFERATIVE BASIS
DK1063969T3 (en) Topical oil-in-water formulation as a carrier to produce a reduced irritant effect
SE9904132D0 (en) Pharmaceutical composition for treatment of diarrhea